Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Definium Therapeutics, Inc.NASDAQ: DFTX

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $46.14M rose 48.9% year over year, behind the +60.3% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +48.2% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +48.9% toward the trailing-twelve-month pace of +60.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$46.14M-5.2% QoQ
Last fiscal yearDec 2025
$117.67M+80.2% YoY
LTMSep 2026
$169.81M+60.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.9%——
1 year+80.2%——
3-year CAGR+48.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
117.67M USD
Year-over-year change
+80.2%
4-year CAGR
+35.6%

Research & Development vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +60.3% is the 3rd highest of 10, against a peer median of +19.0%.
  • Over three fiscal years its annual growth of +48.2% compares with a peer median of +24.0%.
DFTX Competitors
Research & Development for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$5.27B USD+80515.8%-26.7%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$289.11M USD+17.6%+19.9%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$187.86M USD-3.5%+46.8%24.2%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$171.97M USD+136.8%+73.1%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$169.81M USD+60.3%+48.2%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M USD-21.6%+18.9%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.93M USD+58.7%+118.3%539.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M USD+19.0%+24.4%—
GHRSGH Research PLCLTM Mar 2026$43.27M USD+26.5%+23.7%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$28.47M USD—+131.7%—
ATHEAlterity Therapeutics LimitedFY2025A$14.4M AUD-22.7%-0.8%264.8%
Peer median (excluding DFTX) —+19.0%+24.0%264.8%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue003.16M527K0
Gross Profit00(3.16M)(527K)0
Gross Margin—————
Research & Development34.79M36.17M48.96M65.3M117.67M
Selling, General & Admin59.07M30.16M41.74M38.62M48.64M
Operating Expenses93.85M66.33M90.7M103.39M166.31M
Depreciation & Amortization2.62M3.18M3.16M527K0
EBITDA(91.22M)(52.12M)(92.57M)(105.87M)(178.31M)
EBITDA Margin—————
Operating Income(93.85M)(66.33M)(93.87M)(103.92M)(166.31M)
Operating Margin—————
Interest Income01.5M5.58M11.56M10.96M
Interest Expense359K1.5M920K2.28M5.48M
Other Income / Expenses(339K)9.54M(1.87M)(4.76M)(17.48M)
Income Before Tax(94.19M)(56.8M)(95.73M)(108.68M)(183.79M)
Pre-Tax Margin—————
Income Tax Expense(1.16M)0000
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Net Margin—————
EPS (Basic)(3.40)(1.53)(2.44)(1.54)(2.06)
EPS (Diluted)(3.40)(1.53)(2.44)(0.15)(2.06)
Weighted Avg Shares27.38M30.86M39.16M70.46M89.33M
Weighted Avg Shares (Diluted)27.38M30.86M39.16M704.61M89.33M

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.